148 related articles for article (PubMed ID: 19593208)
21. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Porthan K; Viitasalo M; Hiltunen TP; Vaananen H; Dabek J; Suonsyrja T; Hannila-Handelberg T; Virolainen J; Nieminen MS; Toivonen L; Kontula K; Oikarinen L
Ann Med; 2009; 41(1):29-37. PubMed ID: 18608135
[TBL] [Abstract][Full Text] [Related]
22. Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans.
Yan W; Zhang Y; Shan Z; Wang Q; Huang Y; Wang C; Yan K
J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):581-7. PubMed ID: 21810897
[TBL] [Abstract][Full Text] [Related]
23. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH
Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246
[TBL] [Abstract][Full Text] [Related]
24. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation.
Papadimitriou M; Vyzantiadis A; Milionis A; Memmos D; Metaxas P
Life Support Syst; 1983; 1(3):197-205. PubMed ID: 6433115
[TBL] [Abstract][Full Text] [Related]
25. [The captopril test--an aid in the detection of scarring nephropathy as a cause of arterial hypertension in children].
Peco-Antić A; Nastić-Mirić D; Babić D; Kostić M
Srp Arh Celok Lek; 1999; 127(9-10):305-11. PubMed ID: 10649899
[TBL] [Abstract][Full Text] [Related]
26. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment.
Jiang X; Sheng HH; Lin G; Li J; Lu XZ; Cheng YL; Huang J; Xiao HS; Zhan YY
Chin Med J (Engl); 2007 May; 120(9):782-6. PubMed ID: 17531119
[TBL] [Abstract][Full Text] [Related]
27. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition.
Moore N; Dicker P; O'Brien JK; Stojanovic M; Conroy RM; Treumann A; O'Brien ET; Fitzgerald D; Shields D; Stanton AV
Hypertension; 2007 Aug; 50(2):340-7. PubMed ID: 17562974
[TBL] [Abstract][Full Text] [Related]
28. Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Yasar U; Sain-Guven G; Yardimci Y; Kilicarslan A; Babaoglu MO; Bozkurt A
Basic Clin Pharmacol Toxicol; 2011 Aug; 109(2):73-7. PubMed ID: 21332946
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension.
Schwieler JH; Kahan T; Wallén NH; Nussberger J; Hjemdahl P
J Hypertens; 2013 Aug; 31(8):1676-82. PubMed ID: 23625113
[TBL] [Abstract][Full Text] [Related]
30. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan.
Yin T; Maekawa K; Kamide K; Saito Y; Hanada H; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Horio T; Takiuchi S; Kawano Y; Minematsu K; Naritomi H; Tomoike H; Sawada J; Miyata T
Hypertens Res; 2008 Aug; 31(8):1549-57. PubMed ID: 18971529
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Hohl M; Lauder L; Sevimli Ö; Tokcan M; Wagmann L; Götzinger F; Schneider C; Hübner U; Lehnert U; Meyer MR; Böhm M; Mahfoud F
Hypertension; 2023 Jun; 80(6):e90-e100. PubMed ID: 36999443
[TBL] [Abstract][Full Text] [Related]
32. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
Zhou K; Donnelly L; Burch L; Tavendale R; Doney AS; Leese G; Hattersley AT; McCarthy MI; Morris AD; Lang CC; Palmer CN; Pearson ER
Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Hiltunen TP; Donner KM; Sarin AP; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F; Glorioso V; Zaninello R; Salvi E; Glorioso N; Boerwinkle E; Turner ST; Johnson JA; Kontula KK
J Am Heart Assoc; 2015 Jan; 4(1):e001521. PubMed ID: 25622599
[TBL] [Abstract][Full Text] [Related]
34. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases.
Joy MS; Dornbrook-Lavender K; Blaisdell J; Hilliard T; Boyette T; Hu Y; Hogan SL; Candiani C; Falk RJ; Goldstein JA
Eur J Clin Pharmacol; 2009 Sep; 65(9):947-53. PubMed ID: 19669737
[TBL] [Abstract][Full Text] [Related]
35. Common genetic variation of beta1- and beta2-adrenergic receptor and response to four classes of antihypertensive treatment.
Suonsyrjä T; Donner K; Hannila-Handelberg T; Fodstad H; Kontula K; Hiltunen TP
Pharmacogenet Genomics; 2010 May; 20(5):342-5. PubMed ID: 20300048
[TBL] [Abstract][Full Text] [Related]
36. The functional c.-2G>C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels.
van Leeuwen N; Caprio M; Blaya C; Fumeron F; Sartorato P; Ronconi V; Giacchetti G; Mantero F; Fernandes-Rosa FL; Simian C; Peyrard S; Zitman FG; Penninx BW; de Kloet ER; Azizi M; Jeunemaitre X; Derijk RH; Zennaro MC
Hypertension; 2010 Nov; 56(5):995-1002. PubMed ID: 20855654
[TBL] [Abstract][Full Text] [Related]
37. Genetic variants in the renin-angiotensin-aldosterone system and blood pressure responses to potassium intake.
He J; Gu D; Kelly TN; Hixson JE; Rao DC; Jaquish CE; Chen J; Zhao Q; Gu C; Huang J; Shimmin LC; Chen JC; Mu J; Ji X; Liu DP; Whelton PK;
J Hypertens; 2011 Sep; 29(9):1719-30. PubMed ID: 21799445
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.
Arnold AC; Okamoto LE; Gamboa A; Shibao C; Raj SR; Robertson D; Biaggioni I
Hypertension; 2013 Mar; 61(3):701-6. PubMed ID: 23266540
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers.
Cabaleiro T; Román M; Ochoa D; Talegón M; Prieto-Pérez R; Wojnicz A; López-Rodríguez R; Novalbos J; Abad-Santos F
Drug Metab Dispos; 2013 Jan; 41(1):224-9. PubMed ID: 23118328
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.
Yasar U; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Clin Pharmacol Ther; 2002 Jan; 71(1):89-98. PubMed ID: 11823761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
